Shigella vaccine - Intellivax

Drug Profile

Shigella vaccine - Intellivax

Latest Information Update: 01 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intellivax
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Shigella infections

Most Recent Events

  • 05 Jun 2001 Intellivax has been acquired by ID Biomedical Corporation
  • 09 Jun 2000 Phase-II clinical trials for Shigella infections in USA (Intranasal)
  • 31 Mar 1999 A phase I study has been added to the adverse events section and the Bacterial Infections immunogenicity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top